GSK, Biological E to form JV for developing polio drug

Completion of transaction is expected in 2013, subject to several conditions including regulatory nod of the JV

Global drug major (GSK) and Hyderabad-based will set up a joint venture (JV) to develop a six-in-one vaccine for polio and other infectious diseases.

and have inked a pact to form a 50:50 JV for the early stage research and development of a six-in-one combination vaccine to protect children in India and other developing countries from polio and other infectious diseases, the two said in a joint statement today.

Completion of the transaction is expected in 2013, subject to several conditions including regulatory approval of the JV, the statement added.

"If approved, the vaccine, which would combine GSK's injectable polio vaccine and Biological E's pentavalent vaccine for diphtheria, tetanus, whooping cough [whole cell pertussis], hepatitis B, and Haemophilus influenza type b, could be the first of its kind," the statement said.

The JV will bear the development costs for the candidate vaccine, which is expected to enter phase 1 development in the next two years, it added.

"A very small initial cash investment will be made by both to cover start-up costs for the JV and subsequent development costs will be split equally," it said.

The vaccine would enable fewer injections for children thereby improving compliance in immunisation schedules, the statement added.

Chairman Vijay Kumar Datla said that the company expects to leverage the partnership to accelerate the development of the hexavalent vaccine and make IPV accessible for developing countries in the post eradication phase for polio.

"The partnership reinforces the commitment of both to support the World Health Organisation's global polio eradication programme," the statement said.

image
Business Standard
177 22
Business Standard

GSK, Biological E to form JV for developing polio drug

Completion of transaction is expected in 2013, subject to several conditions including regulatory nod of the JV

Press Trust of India  |  New Delhi 

Global drug major (GSK) and Hyderabad-based will set up a joint venture (JV) to develop a six-in-one vaccine for polio and other infectious diseases.

and have inked a pact to form a 50:50 JV for the early stage research and development of a six-in-one combination vaccine to protect children in India and other developing countries from polio and other infectious diseases, the two said in a joint statement today.

Completion of the transaction is expected in 2013, subject to several conditions including regulatory approval of the JV, the statement added.

"If approved, the vaccine, which would combine GSK's injectable polio vaccine and Biological E's pentavalent vaccine for diphtheria, tetanus, whooping cough [whole cell pertussis], hepatitis B, and Haemophilus influenza type b, could be the first of its kind," the statement said.

The JV will bear the development costs for the candidate vaccine, which is expected to enter phase 1 development in the next two years, it added.

"A very small initial cash investment will be made by both to cover start-up costs for the JV and subsequent development costs will be split equally," it said.

The vaccine would enable fewer injections for children thereby improving compliance in immunisation schedules, the statement added.

Chairman Vijay Kumar Datla said that the company expects to leverage the partnership to accelerate the development of the hexavalent vaccine and make IPV accessible for developing countries in the post eradication phase for polio.

"The partnership reinforces the commitment of both to support the World Health Organisation's global polio eradication programme," the statement said.

RECOMMENDED FOR YOU

GSK, Biological E to form JV for developing polio drug

Completion of transaction is expected in 2013, subject to several conditions including regulatory nod of the JV

Global drug major GlaxoSmithKline (GSK) and Hyderabad-based Biological E will set up a joint venture (JV) to develop a six-in-one vaccine for polio and other infectious diseases.

Global drug major (GSK) and Hyderabad-based will set up a joint venture (JV) to develop a six-in-one vaccine for polio and other infectious diseases.

and have inked a pact to form a 50:50 JV for the early stage research and development of a six-in-one combination vaccine to protect children in India and other developing countries from polio and other infectious diseases, the two said in a joint statement today.

Completion of the transaction is expected in 2013, subject to several conditions including regulatory approval of the JV, the statement added.

"If approved, the vaccine, which would combine GSK's injectable polio vaccine and Biological E's pentavalent vaccine for diphtheria, tetanus, whooping cough [whole cell pertussis], hepatitis B, and Haemophilus influenza type b, could be the first of its kind," the statement said.

The JV will bear the development costs for the candidate vaccine, which is expected to enter phase 1 development in the next two years, it added.

"A very small initial cash investment will be made by both to cover start-up costs for the JV and subsequent development costs will be split equally," it said.

The vaccine would enable fewer injections for children thereby improving compliance in immunisation schedules, the statement added.

Chairman Vijay Kumar Datla said that the company expects to leverage the partnership to accelerate the development of the hexavalent vaccine and make IPV accessible for developing countries in the post eradication phase for polio.

"The partnership reinforces the commitment of both to support the World Health Organisation's global polio eradication programme," the statement said.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard